Advances in treatment of HER2-positive gastric cancer

doi:10.3969/j.issn.1009-976X.2014.06.029

Abstract

Abstract: 【Abstract】〓Gastric cancer is the fourth most common malignancy in the world..Surgery. chemotherapy and radiotherapy are the major strategies for treatment, but the efficacy is limited. With the development of molecular biology,.the gastric cancer target genes are detected and the targeted medicine is used for clinical purpose,.especially for HER2 gene and the HER2-targeted medicine which give new hope for HER2-positive gastric cancer..This article focuses on the advance of treatment in HER2-positive gastric cancer.

Key words: Gastric cancer, HER2, Trastuzumab

摘要： 【摘要】〓胃癌居全球恶性肿瘤发病率排行榜的第四位,手术、放疗和化疗的综合治疗为主要治疗手段,但疗效有限。随着胃癌分子生物学的发展,胃癌的靶基因被检测,针对靶基因的靶向药物亦被逐渐用于胃癌的临床治疗,尤其是HER2靶基因的发现及相关靶向药物的治疗给胃癌患者带来了新的希望。本文就HER2阳性胃癌的治疗进展作一综述。

关键词: 胃癌, HER2, 曲妥珠单抗

CLC Number:

R735.2

Mao Wu, Xu Yunji, Liang Qingmo. Advances in treatment of HER2-positive gastric cancer[J]. Lingnan Modern Clinics in Surgery, 2014, 14(06): 711-715.

毛武许云吉梁庆模. HER2阳性胃癌的治疗进展[J]. 岭南现代临床外科, 2014, 14(06): 711-715.

References

[1]Catalano V, Labianca R, Beretta GD, et al.Gastric cancer[J].Crit Rev Oncol Hematol, 2009, 71(2):127-164
[2]Pasini F, Fraccon AP, DE Manzoni G.The role of chemotherapy in metastatic gastric cancer[J].Anticancer Res, 2011, 31(10):3543-3554
[3]American Cancer Society, Survival Rates for Stomach Cancer by Stage, 2013, (accessed 05.09.13)
[4]Gschwind A, Fischer OM, Ullrich A.The discoveryof receptor tyrosine kinases: targets for cancer therapy[J].Nat RevCancer, 2004, 4(5):361-370
[5]Shepard HM, Brdlik CM, Schreiber H.Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family[J].J Clin Invest, 2008, 118(11):3574-3581
[6]Milanezi F, Carvalho S, Schnfitt FC.EGFRHER2 in breast cancer: a biological approach for molecular diagnosis and therapy[J].Expe Rev Mol Diagu, 2008, 8(4):417-437
[7]Rubin I, Yarden Y.The basic biology of HER2 [J].Ann Oncol, 2001, 12(suppl 1):3-8
[8]Sakai K, Mori S, Kawamoto T, et al.Expression of epidermal growth factor receptors on human gastric epithelia and gastric carcinomas[J].Natl Cancer Inst, 1986, 77(5):1047-1052
[9]Meza-Junco J, Au HJ, sawyer MB.Trastuzumab for gastric cancer[J].Expert Opin Biol Ther, 2009, 9(12):1543-1551
[10]Grabsh H, Sivakumar S, Gray S, et al.Her2 erpression in gastric cancer rare,heterogeneous and of no prognostic value-conclusions from 924 cases of two independent case seris[J].Cell Oncol, 2010, 32(1):57-65
[11]Bang YJ, Cutsem EV, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2 positive advanced gastric or gastroesophageal junction cancer (ToGA):a phase 3,open-lable,randomized controlled trial[J].Lancet, 2010, 376(9742):687-697
[12]Matsubara J, Yamada Y, Hirashima Y, et al.Impact of insulin like growth factor type1 receptor,epidermal growth factor receptor,and Her2 expressions on outcomes of patients with gastric cancer[J].Clin Cancer Res, 2008, 14(10):3022-3029
[13]Yan B, Yau EX, Bte Omar SS, et al.A study of HER2 gene ampli?cation and protein expression in gastric cancer[J].J Clin Pathol, 2010, 63(9):839-842
[14]Kim KC, Koh YW, Chang HM, et al.Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays[J].Ann Surg Oncol, 2011, 18(10):2833-2840
[15]Im SA, Kim JW, Kim JS, et al.Clinicopathologic characteristics of patients with stage IIIIV (M(0)) advanced gastric cancer,according to HER2 status assessed by immunohistochemistry and ?uorescence in situ hybridization[J].Diagn Mol Pathol, 2011, 20(2):94-100
[16]Kunz PL, Mojtahed A, Fisher GA, et al.HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis with Proposed Approach to HER2 Assessment[J].Appl Immunohistochem Mol Morphol, 2012, 20(1):13-24
[17]Wang YY, Ye ZY, Li L, et al.ADAM 10 is associated with gastric cancer progression and prognosis of patients[J].J Surg Oncol, 2011, 103(2):116-123
[18]Hofmann M, Stoss O, Shi D, et al.Assessment of a HER2 scoring system for gastric cancer: results from a validation study[J].Histopathology, 2008, 52(7):797-805
[19]Yonemura Y, Ninomiya I, Yamaguchi A, et al.Evaluation of immunoreactivity for erbB-2 protein as a marker of poor shortterm prognosis in gastric cancer[J].Cancer Res, 1991, 51(3):1034-1038
[20]Park DI, Yun JW, Park JH, et al.HER-2neu amplification is an independent prognostic factor in gastric cancer[J].Dig Dis Sci, 2006, 51(8):1371-1379
[21]Barros-Silva JD, Leitao D, Afonso L, et al.Association of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patients[J].Br J Cancer, 2009, 100(3):487-493
[22]Grabsch H, Sivakumar S, Gray S, et al.HER2 expression in gastric cancer: rare,heterogeneous and of no prognostic value –conclusions from 924 cases of two independent case series[J].Cell Oncol, 2010, 32(1):57-65
[23]Wagner AD, Unverzagt S, Grothe W, et al.Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2010, (3):CD004064.
[24]Wagner AD, Grothe W, Haerting J, et al.Chemotherapy in advanced gastric cancer: a systematic review and meta analysis based on aggregate data[J].J Clin Oncol, 2006, 24(18):2903-2909
[25]Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.Phase III study of docetaxel and cisplatin plus ?uorouracil compared with cisplatin and ?uorouracil as ?rst-line therapy for advanced gastric cancer: a report of the V325 study group[J].J Clin Oncol, 2006, 24(31):4991-4997
[26]Lordick F, Lorenzen S, Yamada Y, et al.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?[J].[J].Gastric Cancer, 2014, 17(2):213-215
[27]Cunningham D, Starling N, Rao S, et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J].New Engl J Med, 2008, 358(1):36-46
[28]Power DG, Kelsen DP, Shah MA.Advanced gastric cancer–slow but steady progress[J].Cancer Treat Rev, 2010, 36(5):384-392
[29]Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label,randomised controlled trial[J].Lancet, 2010, 376(9742):687-697
[30]Power DG, Kelsen DP, Shah MA.Advanced gastric cancer–slow but steady progress[J].Cancer Treat Rev, 2010, 36(5):384-392
[31]Dai GH, Shi Y, Chen L, et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression[J].Hepatogastroenterology, 2012, 59(120):2439-2444
[32]Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].New Engl J Med, 2006, 355(1):11-20
[33]Rivera F, Jiménez P, Garcia Alfonso P, et al.NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma-R0 resection, pCR, and toxicity analysis[J].J Clin Oncol, 2013, 31(suppl):4098-4098
[34]Iqbal S, Goldman B, Fenoglio-Preiser CM, et al.Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer[J].Ann Oncol, 2011, 22(12):2610-2615
[35]Chen CT, Kim H, Liska D, et al.MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells[J].Mol Cancer Ther, 2012, 11(3):660-669
[36]Oshima Y, Tanaka H, Murakami H, et al.Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines[J].Gastric Cancer, 2014, 17(3):450-462